{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.17","upperLimit":"6.18","value":"4.34"},{"groupId":"OG001","lowerLimit":"6.08","upperLimit":"19.25","value":"8.31"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"description":"Duration of objective response was measured from the time the criteria were met for complete response or partial response to the first date that recurrent or progressive disease was objectively documented.","dispersionType":"95% Confidence Interval","groups":[{"description":"temozolomide 150 mg/m2/day PO, on 7 consecutive days every 14 days (\"7 days on / 7 days off\" continuously)","id":"OG000","title":"Temozolomide"},{"description":"dacarbazine 1000 mg/m2 IV, on Day 1 +/- 3 days every 3 weeks","id":"OG001","title":"Dacarbazine"}],"paramType":"MEDIAN","populationDescription":"All responders","reportingStatus":"POSTED","timeFrame":"Treatment continued until disease progression or unacceptable toxicity.","title":"Duration of Objective Response","type":"SECONDARY","unitOfMeasure":"Months"}